Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
-
Canaccord Genuity Morning Coffee on Merck & Co. (MRK) and Sanofi-Aventis (SNY): So Long, Farewell, Au Revoir
-
Top 10 News Items 2/14-2/18: NYSE Euronext/Deutsche Boerse Announces Definitive Agreement, Sanofi, Genzyme Finally Approve Deal, Stocks Continue Higher, Up 28% Since Sept.
-
Canaccord Genuity Morning Coffee on Sanofi-Aventis (SNY) and Genzyme (GENZ): An Extra $5 Will Help The Medicine Go Down
-
Notable ETF Movers of the Day 02/16: (XRT) (USO) (TAN) Higher; (UNG) (VXX) (UUP) Lower
-
Trading Radar for 02/16: NVIDIA (NVDA), Deere (DE), Genzyme (GENZ), CBS Corp. (CBS), NetApp (NTAP) Report
-
Notable Mergers and Acquisitions of the Day 11/18: VRGY/LTXC, CAH, GENZ
-
Sanofi-aventis (SNY) Seeks Clarification from Genzyme (GENZ) Over Potential Board Actions
-
sanofi-aventis (SNY) Expands Presence in China with $520.6M Acquisition of BMP Sunstone (BJGP)
-
Morgan Joseph Reiterates a 'Buy' Rating on Genzyme (GENZ); Continue To Like Fundamentals
-
Trading Radar for 10/20: Morgan Stanley (MS), US Bancorp (USB), Delta Air (DAL), eBay (EBAY), Xilinx (LNX) Report
